LOGIN  |  REGISTER
Amneal Pharmaceuticals

Akebia Therapeutics (NASDAQ: AKBA) Stock Quote

Last Trade: US$1.83 -0.41 -18.30
Volume: 60,390,756
5-Day Change: -5.67%
YTD Change: 47.58%
Market Cap: US$383.150M

Latest News From Akebia Therapeutics

Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia Akebia's Launch Strategy Developed to Drive Toward a Potential New Oral Standard of Care Company to Host Conference Call on Thursday, March 28 at 8:00 AM ET CAMBRIDGE, Mass. , March 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney... Read More
Potential vadadustat U.S. approval on PDUFA date of March 27, 2024 Strengthened balance sheet with $55.0 million term loan financing and $26.0 million in proceeds from ATM Reported 2023 Auryxia (ferric citrate) net product revenue of $170.3 million CAMBRIDGE, Mass. , March 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by... Read More
CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024 . Akebia will not host a conference call due to the proximity to the anticipated March 27, 2024 Prescription Drug User Fee Act... Read More
CAMBRIDGE, Mass. , March 1, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 4,000 shares of Akebia's common stock on February 29, 2024 , as an inducement material to such employee entering into employment with Akebia. The options were... Read More
CAMBRIDGE, Mass. , Feb. 2, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 856,950 shares of Akebia's common stock on January 31, 2024 , including an option to purchase 454,950 shares to Nik Grund , Akebia's newly hired Chief Commercial... Read More
Strengthens Balance Sheet Ahead of Potential Vadadustat Approval on March 27, 2024 CAMBRIDGE, Mass. , Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock. The loan provides Akebia with up to $55.0 million of... Read More
CAMBRIDGE, Mass. , Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty... Read More
CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's common stock on December 29, 2023 , as inducements material to such employee entering into employment with Akebia. The options were... Read More
CAMBRIDGE, Mass. , Dec. 20, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11 th , 2024 at 11:15 a.m. PST . The 42 nd Annual J.P. Morgan Healthcare Conference... Read More
CAMBRIDGE, Mass. , Dec. 1, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 31,000 shares of Akebia's common stock on November 30, 2023 , as inducements material to such employee entering into employment with Akebia. The options were... Read More
CAMBRIDGE, Mass. , Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference on Tuesday, November 28 th at 10:30 a.m. EST . The Piper Sandler Healthcare... Read More
Akebia to host conference call at 8:00 a.m. ET Vadadustat NDA assigned a PDUFA date of March 27, 2024 Vadadustat approved in 36 countries, including Australia and Taiwan Akebia strengthens cash position modifying Pharmakon loan Auryxia® (ferric citrate) quarterly net product revenue of $40.1 million CAMBRIDGE, Mass. , Nov. 8, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with... Read More
Company Strengthens Cash Position in Advance of Potential Vadadustat Launch CAMBRIDGE, Mass. , Nov. 2, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has amended the terms of its loan agreement with Pharmakon Advisors, LP, the investment manager of the BioPharma Credit funds that it... Read More
CAMBRIDGE, Mass. , Nov. 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 61,000 shares of Akebia's common stock on October 31, 2023 , as an inducement material to such employee entering into employment with Akebia. The options were granted... Read More
Akebia to Host Conference Call on November 8 th at 8:00 a.m. ET CAMBRIDGE, Mass. , Oct. 31, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2023 on Wednesday, November 8, 2023 , prior to the open of financial markets. Akebia will host a conference call on Wednesday, November 8 at 8:00 a.m. ET to discuss its... Read More
March 27, 2024 Set as User Fee Goal Date CAMBRIDGE, Mass. , Oct. 25, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the U.S. Food and Drug Administration (FDA) has acknowledged that the resubmission to its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic... Read More
CAMBRIDGE, Mass. , Oct. 18, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2023 (ASN Kidney Week), which will take place at the Pennsylvania Convention Center in Philadelphia from November 2-5 , 2023.... Read More
CAMBRIDGE, Mass. , Oct. 3, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 2,000 shares of Akebia's common stock on September 29, 2023 , as an inducement material to such employee entering into employment with Akebia. The options were... Read More
CAMBRIDGE, Mass. , Sept. 28, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the... Read More
CAMBRIDGE, Mass. , Sept. 26, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that Australia's Therapeutic Goods Administration (TGA) has granted approval for Vafseo ® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. The TGA approval for Vafseo is based... Read More
CAMBRIDGE, Mass. , Sept. 6, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc . (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the H.C. Wainwright 25 th Annual Global Investment Conference on Monday, September 11, 2023 at 9:30 a.m. ET . The H.C. Wainwright Global Investment... Read More
CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 67,000 shares of Akebia's common stock on August 31, 2023 , as inducements material to such employee entering into employment with Akebia. The options were... Read More
Akebia to host conference call on August 25, 2023 at 9:00 a.m. ET Expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023 Reports Auryxia ® (ferric citrate) net product revenue of $42.2 million for Q2 2023 and reaffirms 2023 net product revenue guidance of $175.0 - $180.0 million CAMBRIDGE, Mass. , Aug. 25, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq:... Read More
Akebia Received Type A Meeting Minutes from the FDA CAMBRIDGE, Mass. , Aug. 24, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company expects to resubmit its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic kidney disease in adult patients on... Read More
Akebia to Host Conference Call on August 25 th at 9:00 a.m. ET CAMBRIDGE, Mass. , Aug. 23, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2023 on Friday, August 25, 2023 . Akebia will host a conference call on... Read More
Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing CAMBRIDGE, Mass. , Aug. 17, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2023 by Friday, August 25, 2023 prior to the open of... Read More
Akebia announces late filing of its second quarter earnings and Form 10-Q Akebia reaffirms 2023 net product revenue guidance of $175 - $180 million Akebia believes its cash resources as of June 30, 2023 will be sufficient to fund its current operating plan through at least the next twelve months Akebia expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023... Read More
CAMBRIDGE, Mass. , Aug. 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted Ellen Snow , Akebia's newly-hired Senior Vice President, Chief Financial Officer and Treasurer, options to purchase 560,000 shares of Akebia's common stock on July 31, 2023 . The options were granted as an inducement material... Read More
CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2 nd Annual Kidney Conference, which will take place as a virtual event on Tuesday, July 25, 2023 . During the... Read More
CAMBRIDGE, Mass. , July 18, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia completed an End of Dispute Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss Akebia's forthcoming resubmission of its New Drug Application (NDA) for vadadustat as a treatment... Read More
CAMBRIDGE, Mass. , July 5, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 24,000 shares of Akebia's common stock on June 30, 2023 , as inducements material to such employee entering into employment with Akebia. The options were granted in... Read More
CAMBRIDGE, Mass. , June 29, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced topline results from IMPACT, a Phase 4 collaborative study investigating the impact of Auryxia® (ferric citrate), when used as the primary phosphate-lowering therapy, on the utilization of erythropoiesis-stimulating... Read More
CAMBRIDGE, Mass. , June 20, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization for Vafseo ® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance... Read More
CAMBRIDGE, Mass. , June 13, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Ellen Snow is joining Akebia as its new Senior Vice President, Chief Financial Officer and Treasurer, beginning on July 17, 2023 . Ms. Snow will join Akebia from Pear Therapeutics, Inc., where she has served as... Read More
CAMBRIDGE, Mass. , June 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m. ET . In his presentation, Mr. Butler will discuss recent regulatory updates... Read More
CAMBRIDGE, Mass. , June 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 29,000 shares of Akebia's common stock on May 31, 2023 , as inducements material to such employee entering into employment with Akebia. The options were granted in... Read More
FDA denies formal dispute resolution, but outlines path to resubmit NDA for dialysis-dependent patients without new clinical studies Akebia plans to request Type A meeting and then resubmit NDA Akebia will host a conference call on Tuesday, May 30 at 8:30 a.m. ET CAMBRIDGE, Mass. , May 30, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of... Read More
Medice brings extensive expertise in nephrology and an established European dialysis business Akebia to receive a $10 million upfront payment, potential for up to $100 million in commercial milestone payments, and tiered royalties up to 30% of net sales in dialysis Akebia retains majority of economics in non-dialysis indication if approved by EMA and retains rights to all other indications CAMBRIDGE, Mass. , May 25, 2023... Read More
CAMBRIDGE, Mass. , May 22, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Akebia has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule... Read More
CAMBRIDGE, Mass. , May 22, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Vafseo ® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on... Read More
Akebia to host conference call on May 8 at 8:30 a.m. ET Announced vadadustat is now approved in 32 countries following European Commission marketing authorization Expects a response to Formal Dispute Resolution from FDA within next 30 days Released positive top-line results from vadadustat alternative dosing study Reports Auryxia ® (ferric citrate) net product revenue of $34.8M for Q1 2023 Affirms 2023 Auryxia net product... Read More
Akebia to Host Conference Call CAMBRIDGE, Mass. , May 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2023 on Monday, May 8, 2023 , prior to the open of financial markets. Akebia will host a conference call on... Read More
CAMBRIDGE, Mass. , April 25, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that the European Commission (EC) has granted marketing authorisation for Vafseo™ (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. The approval is... Read More
Webcast Scheduled for Friday, April 21 at 8:00 a.m. ET Stockholders are invited to submit questions in advance CAMBRIDGE, Mass. , April 14, 2023 /PRNewswire/ -- A kebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will host a stockholder information session on Friday, April 21 at 8:00 a.m. ET to discuss its... Read More
Meeting adjourned to Thursday, May 4, 2023 at 10:00 a.m. Eastern Time CAMBRIDGE, Mass. , April 11, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it adjourned, without conducting any business, the special meeting of stockholders (the "Special Meeting") on Tuesday, April 11, 2023 to allow... Read More
CAMBRIDGE, Mass. , April 7, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present posters at the National Kidney Foundation (NKF) Spring Clinical Meetings 2023 (SCM23), which will take place on demand and live in Austin, Texas on April 11 – 15, 2023. Abstracts are available... Read More
CAMBRIDGE, Mass. , April 4, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 4,000 shares of Akebia's common stock on March 31, 2023 , as an inducement material to such employee entering into employment with Akebia. The options were granted... Read More
Data demonstrated that vadadustat met the primary and secondary efficacy endpoints and was non-inferior to an ESA as a treatment for anemia due to chronic kidney disease when administered three times a week at the time of dialysis Vadadustat demonstrated a similar safety profile to long-acting ESA when used three times a week CAMBRIDGE, Mass. , April 3, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a... Read More
CAMBRIDGE, Mass. , March 30, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company met with the U.S. Food and Drug Administration (FDA) Office of New Drugs (OND) deciding authority to discuss Akebia's Formal Dispute Resolution regarding the Complete Response Letter for vadadustat... Read More
CAMBRIDGE, Mass. , March 24, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that it has filed a revised definitive proxy statement with the Securities and Exchange Commission (SEC) in connection with a special meeting (Special Meeting) of stockholders scheduled on April 11, 2023 at 10:00 a.m. ET in... Read More
Akebia to host conference call on March 9 at 8:30 a.m. ET Receives positive CHMP opinion for Vafseo™ (vadadustat); anticipates potential Marketing Authorization in Europe in May 2023 Reports Auryxia ® (ferric citrate) net product revenue of $177.1M for 2022, an increase of approximately 24.5% over 2021 Sets 2023 Auryxia net product revenue guidance at $175 - $180M CAMBRIDGE, Mass. , March 9, 2023 /PRNewswire/ -- Akebia... Read More
Akebia to Host Conference Call CAMBRIDGE, Mass. , March 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year ended December 30, 2022 on Thursday, March 9 prior to the open of financial markets. Akebia will host a... Read More
CAMBRIDGE, Mass. , Feb. 23, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (NASDAQ: AKBA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve Vafseo™ (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anaemia... Read More
CAMBRIDGE, Mass. , Feb. 21, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received a second interim response from the U.S. Food and Drug Administration to its Formal Dispute Resolution Request regarding the Complete Response Letter for vadadustat received in March 2022.... Read More
CAMBRIDGE, Mass. , Feb. 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 18,000 shares of Akebia's common stock on January 31, 2023 , as inducements material to such employee entering into employment with Akebia. The options were... Read More
CAMBRIDGE, Mass. , Jan. 3, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 2,000 shares of Akebia's common stock on December 30, 2022 , as an inducement material to such employee entering into employment with Akebia. The options were granted... Read More
CAMBRIDGE, Mass. , Dec. 22, 2022 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received an interim response from the U.S. Food and Drug Administration (FDA) to its Formal Dispute Resolution Request regarding the Complete Response Letter received in March 2022 for vadadustat,... Read More
CAMBRIDGE, Mass. , Dec. 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 3,000 shares of Akebia's common stock on November 30, 2022 , as an inducement material to such employee entering into employment with Akebia. The options were granted... Read More
Compass Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB